Abstract
Objective To investigate the diagnostic value and monitoring application of anti-phospholipase A2 receptor antibodies (PLA2R) in patients with idiopathic membranous nephropathy (IMN). Methods A retrospective study was used. 48 patients were diagnosed as idiopathic membranous nephropathy by puncturing kidney from January of 2013 to June of 2014 in the Hospital of Liaoning Traditional Chinese Medical University and Shengjing Hospital of China Medical University were included. 43 patients were diagnosed as non-idiopathic membranous nephropathy (NIMN). 35 healthy volunteers were selected as control groups. Serum PLA2R were detected by indirect immunofluorescence. The intensity of antibodies fluorescence and the level of urine protein in 24 hours(24 h PRO), serum UREA, serum CYSC, serum UA, GFR were compared in each groups. Measurement data was shown as mean±standard deviation; Count data was shown as frequency or composition, t test and χ2 test were used as statistical method. Results (1) Among 48 cases with IMN, 37 cases showed positive PLA2R (positive rate 77.08%). All of cases were negative in NIMN group. The sensitivity and the specificity of serum PLA2R were 77.08% and 100%. (2) Compared with control groups, the levels of UREA, CYSC and UA were found statistically significant differences in patients with IMN (P 0.05). (3) Positive correlation were found between 24 h PRO(r=0.877, P=0.00), serum UA (r=0.766, P=0.00) with the level of PLA2R antibodies fluorescence intensity.(4) There were no correlation between serum PLA2R antibody with IMN pathology aging (r=0.087, 0.194, 0.182; P=0.598, 0.399, 0.667). PLA2R positive rate(Ⅰstage: 37.50%, Ⅱstage: 84.85%, Ⅲstage 85.71%) may increases with the increasing of illness severity. Conclusion Serum PLA2R antibody would be a new laboratory diagnosis standard in patients with IMN.(Chin J Lab Med, 2015, 38: 595-599) Key words: Glomerulonephritis, membranous; Receptors, phospholipase A2; Autoantibodies; Fluorescent antibody technique, indirect
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
